{
    "symbol": "PBLA",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-14 15:05:21",
    "content": "  We have commenced screening for eligible patients with enrollment expected to complete in approximately 12 months after the first patient is enrolled, supporting the advancement into the ASPIRE trial was data announced in January of this year at the ASCO GI meeting, which included an objective response rate of 48%, a disease control rate of 76%, an immediate overall survival of 12 months, which at the time of the poster presentation was not yet final."
}